EPI-331
Asset
CRISPR-based epigenome editing provides a mutation-agnostic approach to treating Duchenne muscular dystrophy.
- Stage
- Stage not known
- Modality
- Not known
- Target
- Not known
- 0
- Indications
- 0
- Trials
- 1
- Developer
Indications
0In the full profile
- Owner and partners1
Every asset’s record: target, stage, trials and the evidence behind it.